期刊文献+

中药塌渍联合肿瘤坏死因子拮抗剂治疗活动性强直性脊柱炎的临床观察

Clinical Observation of Patients With Active Ankylosing Spondylitis Treated by Combination of Chinese Medicine Collapse Stains and Tumor Necrosis Factor
下载PDF
导出
摘要 目的探讨中药塌渍联合肿瘤坏死因子拮抗剂治疗活动性强直性脊柱炎的临床效果。方法将活动性强直性脊柱炎患者74随机分两组,对照组37例采用肿瘤坏死因子拮抗剂治疗,观察组37例采用中药塌渍联合肿瘤坏死因子拮抗剂治疗。结果观察组晨僵时间、红细胞沉降率、C反应蛋白、VAS评分、BASDAI评分、BASFI评分低于对照组,而治疗优良率高于对照组(P<0.05)。结论中药塌渍联合肿瘤坏死因子拮抗剂是治疗活动性强直性脊柱炎的有效方法,临床疗效显著。 Objective To investigate the clinical effect of treating ankylosing spondylitis with the combination of Chinese medicine collapse stains and tumor necrosis factor antagonist. Methods 74 patients with active ankylosing spondylitis were randomly divided into two groups, 37 cases in control group treated TNF antagonist. 37 cases in observation group treated collapse stains combined with tumor necrosis factor antagonist treatment. Results The observation group of morning stiffness time, erythrocyte sedimentation rate, C reactive protein, VAS score, BASDAI score, BASFI score lower than the control group, and the treatment was higher than that of control group(P0.05). Conclusion The combination of Chinese medicine and tumor necrosis factor antagonist is an effective method to treat active ankylosing spondylitis, and it is helpful to improve clinical effect.
作者 姜志宇
出处 《中国继续医学教育》 2016年第31期192-193,共2页 China Continuing Medical Education
关键词 中药塌渍 肿瘤坏死因子拮抗剂 活动性强直性脊柱炎 Traditional Chinese medicine collapse stains Tumor necrosis factor antagonist Active ankylosing spondylitis
  • 相关文献

参考文献9

二级参考文献75

  • 1郝双林,赵俊.临床疼痛的测定方法及其评价[J].国外医学(麻醉学与复苏分册),1993,14(4):228-230. 被引量:203
  • 2林智明,古洁若.强直性脊柱炎治疗现状及其进展[J].国际内科学杂志,2007,34(1):39-42. 被引量:17
  • 3强军,周志宏,高万勤,傅建斌,李云东.强直性脊柱炎髋关节病变的早期X线征象探讨[J].中国医学影像技术,2007,23(1):109-111. 被引量:12
  • 4盛华强,赵斌.强直性脊柱炎的早期骶髂关节炎:MRI与临床及实验室相关性[J].实用放射学杂志,2007,23(6):774-777. 被引量:12
  • 5张明园主编.精神科评定量表手册[M].第2版.长沙:湖南科学技术出版社,2003:207.
  • 6Yan derLinden SM,Valkenburg HA,Cats A. Evaluation of diag-nostic criteria for ankylosing spondylitis:a proposal for modifica-tion of the New York criteria[J]. Arthritis Rheum, 1984,27(6):361-368.
  • 7Stephens LA, Barclay AN, Mason D. Phenotypic characterization of regulatory CD4^+CD25^+ T ceils in rats [J]. Int Immunol, 2004, 16(2): 365-375.
  • 8El Miedany Y, Youssef S, Mehanna A, et al. Defining disease status in ankylosing spindylitis: validation and cross cultural adaptation of Arabic Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylongsing Spondylitis Disease Activity Index (BASDAI), and the Bath Ankylosing Spondylitis Global score (BASG). ClinRheumatol, 2008,27(5) :605-612.
  • 9Spoorenberg A, van Tubergen A, Landewe R, et al. Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology, 2005, 44 (6) : 789- 795.
  • 10Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in anky losing spondylitis. Arthritis Theum, 2005,53(5):703-709.

共引文献158

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部